Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2019 - 07 - 18
点击次数: 0
Positions: COO
Company: Beijing Shenogen Pharma Group Ltd.
个人简介:
Dr. Wang is currently Chief Operating Office of Beijing Shenogen Pharma Group Ltd. And previously the President of Novo Nordisk Research Center China, the first R&D center set up by a global pharmaceutical company in China. Baoping received a BS degree in Applied Chemistry from Shanghai Jiao Tong University in 1982, and a PhD in Genetics from University of Minnesota in 1990. He did his postdoc research at Harvard Medical School where he then served sequentially as an Instructor and Assistant Professor. His research area focused on molecular and cellular immunology. Baoping joined industry when he returned China in 1998 to head a health care group in Novo Nordisk China R&D center. In 2001, Novo Nordisk established a new R&D center based on the health care group, Baoping was the head of the center since its founding. From April 2007, Baoping also served as a Vice President of Novo Nordisk R&D, and from January 2011 through July 2018, as President of Novo Nordisk Research Center China. He has joined Beijing Shenogen Pharma Group Ltd. as Chief Operating Office from August 2018.
发布时间: 2019 - 07 - 11
点击次数: 0
Positions: CEO
Company: Fosun Kite Biotechnology Co. Ltd
个人简介:
Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D. of Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, Cincinnati in the US. He obtained his post-doctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.Richard is very experienced in biopharmaceutical industry. Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
发布时间: 2019 - 07 - 18
点击次数: 0
Positions: Founer&CEO
Company: CARsgen Therapeutics, Ltd
个人简介:
Zonghai Li, MD, Ph.D., is the founder of CARsgen Therapeutics and served as Chief Executive Officer since the company’s inception in 2014. Dr. Li was also the founder of a series of biotech start-up companies in China. Dr. Li also servers as the tenure Professor at Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai JiaoTong University.  Dr. Li is Standing Committee of Gene Therapy Association of China, China Translational Medicine Union,  and Shanghai Immunology Association. Dr. Li graduated from Hunan Medical University (Now XiangYa School of Medicine, Central South University) in 1997. He further acquired his PhD degree from Fudan University in 2005.
发布时间: 2019 - 07 - 11
点击次数: 0
Positions: Executive Vice President
Company: CDIB Capital Group
个人简介:
Robert is the Executive Vice President of CDIB Capital Group and Managing Director of healthcare investments. Prior to joining CDIB, he served as the Principal, Venture Investments at Johnson & Johnson Development Corporation (JJDC), responsible for the venture and private equity investments in life science and healthcare in Asia Pacific region. Prior to JJDC, Robert served as the Director of Business Development & Strategy in Greater China at GlaxoSmithKline, based in Beijing. Prior to that, Robert worked in the Global Corporate Development & Strategy team of Charles River Laboratories, based in Boston, USA, and executed many acquisition and investment transactions in the US, Europe and Asia.Robert holds a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago Booth School of Business and a Master Degree in Medicine (7-year program) from Tongji Medical University. Robert also received the residency training in Urology at Union Hospital, Wuhan China.